Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORFEUS: PRIME-2-CoV_Beta Vaccine Study
NCT05367843Phase 1Terminated
- Sponsor
- Speranza Therapeutics
- Start
- Jun 2022
- Primary completion
- Jul 2023
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of PRIME-2-CoV_Beta in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Speranza Therapeutics. Primary endpoints: Number of participants with solicited local reactions at the injection site, Number of participants with solicited systemic reactions and 1 more. Started Jun 2022; status: terminated.
02
Drugs
PRIME-2-CoV_Beta
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05367843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367843.